secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2026-10-05T12:30:07+00:00
Accession:  0001193125-26-413217
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Immunome amends BMS license, pays $20M and 4,425,487 shares to end royalties and acquire patents
--------------------------------------------------------------------------------

- Immunome amended BMS license on Oct. 2, 2026, removing milestone/royalty obligations and assigning varegacestat (AL102) and AL101 patent rights to Immunome.
- Immunome paid BMS $20.0 million cash and issued 4,425,487 common shares; after payment, Immunome has no milestone, royalty or other payment obligations to BMS under the License Agreement.
- Stock Issuance Agreement requires Immunome to file a resale registration statement by Nov. 16, 2026, effective within 60 days or 5 business days if SEC does not review.
- The 4,425,487 shares were issued under Section 4(a)(2) exemption and were not registered under the Securities Act; BMS received resale registration rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/0001193125-26-413217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/d114908d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-413217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer